Document |
Document Title |
WO/2011/159740A2 |
The present invention generally relates to synthetic methods for preparing tetranor-prostaglandin D, J, E, A, and F metabolites.
|
WO/2011/154754A1 |
The invention pertains to the use of the compounds of the general formula (I) and their pharmaceutically acceptable salts for reduction of inflammation, (I) wherein R represents a hydrogen atom, hydroxyl group, amino group or NH-R' group...
|
WO/2011/095990A2 |
The present invention discloses a process for purification of prostaglandins of formula (1) into enantiomerically pure isomer of formula (2) by reverse phase preparative HPLC, and converting said isomer into prostaglandin derivative of f...
|
WO/2011/091513A1 |
There is provided a crystalline form of Lubiprostone, termed APO-II and methods for making APO-II. APO-II is a polymorphic form of Lubiprostone.
|
WO/2011/063276A1 |
The present invention provides a new crystalline form of bimatoprost, designated as crystalline form II. This new crystalline form is the most stable form known to date of bimatoprost. Moreover, it has been found that bimatoprost crystal...
|
WO/2011/055377A1 |
This invention relates to novel process for the preparation of prostaglandin compounds having formula (K), wherein R is selected from the group consisting of C1-C7 alkyl; C7-C17 aralkyl wherein the aryl group is unsubstituted or substitu...
|
WO/2011/050638A1 |
The crystalline form A of bimatoprost of formula I, its preparation method and use are provided. There are characteristic peaks where diffraction angles 2θ are 3.2±0.2°, 5.5±0.2°, 11.4±0.2°, 16.7±0.2°, 17.6±0.2°, 19.9±0.2°, ...
|
WO/2011/005505A2 |
The present invention provides a method for the purification of a prostaglandin by supercritical fluid chromatography, said method comprising the use of a stationary phase and a mobile phase comprising carbon dioxide, provided that when ...
|
WO/2010/109476A2 |
The present invention relates to an improved process for the preparation of prostaglandin and prostaglandin analogues, particularly PGF2a derivatives.
|
WO/2010/097672A1 |
The invention concerns a new process for the preparation of prostaglandin derivatives, in particular prostaglandin F2α derivatives, for example bimatoprost, latanoprost and travoprost, the new intermediates of said process and their use...
|
WO/2010/096123A2 |
The present invention is directed to novel amino acid prostaglandin salts and methods of making and using them.
|
WO/2009/142967A1 |
Compounds comprising or a pharmaceutically acceptable salt or a prodrug thereof are disclosed, wherein a dashed line represents the presence or absence of a bond; and, wherein Y, A, R, D, and n are as described. Methods, compositions, an...
|
WO/2009/137413A1 |
Compounds comprising formula (I) or a pharmaceutically acceptable salt thereof, are disclosed, wherein B, Y, and A are as described in claims 1-10. Methods, compositions, and medicaments related thereto are also disclosed, for treating b...
|
WO/2009/137411A1 |
Compounds comprising Formula (I) or a pharmaceutically acceptable salt thereof, are disclosed, wherein J1, J2, U1, B, Y, and A are as described in claims 1-16. Methods, compositions, and medicaments related thereto are also disclosed, fo...
|
WO/2009/136281A1 |
Nitroderivatives of prostaglandins having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
|
WO/2009/131977A1 |
Compounds comprising formula (I) or a pharmaceutically acceptable salt thereof, are disclosed, wherein J, B, Y, and A are as described in claims 1-13. Methods, compositions, and medicaments related thereto are also disclosed, for treatin...
|
WO/2009/132093A2 |
Compounds comprising formula (I) or a pharmaceutically acceptable salt thereof, are disclosed, wherein G, B, Y, and A are as described, in claims 1-13 Methods, compositions, and medicaments related thereto are also disclosed, for treatin...
|
WO/2009/121228A2 |
A lubiprostone crystal, its preparation process, its pharmaceutical composition or kit, and its use for the preparation of a pharmaceutical composition for treating gastroenteropathy, especial constipation. The characteristic peaks of 2Î...
|
WO/2009/117467A2 |
Compounds comprising or a pharmaceutically acceptable salt thereof, are disclosed, wherein Y, A, R1, R2, Z and G as described in claims 1-12. Methods, compositions and medicaments related thereto are also disclosed, for treating gloucoma...
|
WO/2009/117388A1 |
Therapeutic compounds are disclosed herein. Methods, compositions, and medicaments related thereto are also disclosed. The compounds described herein are used to treat ocular conditions, bowel disease and baldness.
|
WO/2009/114467A1 |
Compounds comprising formula (I) or a pharmaceutically acceptable salt or a prodrug thereof, are disclosed, wherein Y, A, and B are as described. Methods, compositions, and medicaments related thereto are also disclosed.
|
WO/2009/100057A1 |
11,15, 19-trihydroxy-9-halo-prostaglandin analogues and its use as ocular hypotensive agents. Ocular hypotensive agents are useful in the treatment of a number of various ocular hypertensive conditions, such as post-surgical and post-las...
|
WO/2009/078965A1 |
This present invention relates to an improved process to prepare prostacyclin derivatives. One embodiment provides for an improved process to convert benzindene triol to treprostinil via salts of treprostinil and to purify treprostinil.
|
WO/2009/073432A1 |
Disclosed herein are compounds having formula (I). Therapeutic methods, medicaments, and compositions related thereto are also disclosed.
|
WO/2009/035565A1 |
The present invention provides prostaglandins, compositions, and methods useful for sustained release of a therapeutic agent over an extended period of time. Exemplary prostaglandins are C4-C32 alkyl esters or amides of prostaglandins, f...
|
WO/2009/005172A1 |
Provided is a pharmaceutical combination of a NSAID and a prostaglandin compound of formula (I). The combination of the invention is useful for the indications for NSAID use such as pain, Alzheimer disease and cancer.
|
WO/2009/006370A1 |
Disclosed herein are compounds having formula (I) wherein a dashed line represents the presence or absence of a bond; Y is an organic acid functional group, or an amide or ester thereof; or Y is hydroxymethyl or an ether thereof; or Y is...
|
WO/2009/005171A1 |
Provided is a pharmaceutical combination of an opioid and a prostaglandin compound of formula (I):. The combination of the invention is useful for the indications for opioid use such as pain from various etiologies.
|
WO/2008/146105A1 |
The present invention relates to new prostaglandin derivatives having improved pharmacological activity and enhanced tolerability. They can be employed for the treatment of glaucoma and ocular hypertension.
|
WO/2008/091810A1 |
Disclosed herein are compounds of the formula : Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
|
WO/2007/140136A2 |
Disclosed herein is a compound having a structure [(I)] or a pharmaceutically acceptable salt, or a prodrug thereof. Therapeutic methods, compositions, and medicaments related thereto are also disclosed.
|
WO/2007/140380A2 |
In various aspects, the present teachings provide labeling reagents and sets of labeling reagents containing one or more heavy atom isotopes for the relative quantitation, absolute quantitation, or both, of hydroxylated compounds includi...
|
WO/2007/127639A2 |
This invention relates to novel homotopic prodrugs and medicaments and methods for their preparation, testing and use. In one embodiment, the homotopic prodrug has the general formula (I) wherein (II) is a biologically-active moiety comp...
|
WO/2007/115001A1 |
A compound comprising a prodrug of a prostaglandin EP4 agonist, wherein said prodrug is an ester, ether, or amide of an amino acid is disclosed herein. Maintenance of the colonic mucosal barrier by method comprising administering a thera...
|
WO/2007/091697A2 |
Disclosed is a method for preparing a prostaglandin derivative of formula (A): which comprises reacting an aldehyde represented by formula (1): with a 2-oxoalkyl phosphonate in a reaction solvent under the presence of alkali hydroxide as...
|
WO/2007/057232A1 |
The present invention relates to 9-chloroprostaglandin derivatives of the general formula (I) which may be advantageous for the treatment of fertility problems.
|
WO/2007/056087A1 |
The present invention relates to cyclopentane heptenoic acid-5-cis-2-(3α-hydroxy or lower alkyloxy-5-thienylpentyl)-3, 5-dihydroxy, [1α, 2β, 3α, 5α] compounds, lower alkyl, hydroxyl lower alkyl and indole lower alkyl amides and este...
|
WO/2007/000641A2 |
Nitroderivatives of prostaglandin amides having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
|
WO/2007/000642A1 |
Nitroderivatives of fluoroprostaglandins having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
|
WO/2006/137472A1 |
A prostaglandin derivative represented by the formula: (I) wherein R1 represents a hydrogen atom, an alkyl group having 1 to 4 carbon atoms or an alkenyl group having 2 to 4 carbon atoms; X represents an ethylene group, a trimethylene gr...
|
WO/2006/112742A2 |
Invention relates to the process for preparation of 13,14-dihydro-PGF2&agr derivatives of R or S configuration at carbon atom in omega chain substituted by hydroxyl, represented by formula (I), wherein the meaning of substituents is defi...
|
WO/2006/101244A2 |
Provided is a method and composition for treating mucosal disorders using a specific prostaglandin compound. The prostaglandin compound induces a conformational change in the tight junction that results in recovery of mucosal barrier fun...
|
WO/2006/101867A2 |
Disclosed herein is a method comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound having a structure according to Formula I wherein X, Y, B, R2, R3,...
|
WO/2006/063179A1 |
Compounds comprising the formula (I) are disclosed, wherein Y, A, X, R, D, and n are as described. A compound comprising a prostaglandin EP2 selective agonist wherein the &ohgr -chain comprises a substituted phenyl, wherein at least one ...
|
WO/2006/058063A1 |
Disclosed herein are compounds comprising Formula (I), or a pharmaceutically acceptable salt or a prodrug thereof; wherein Y, A, B, J, and E are further described. Methods, compositions, and medicaments related thereto are also disclosed.
|
WO/2006/055481A1 |
Disclosed herein are compounds comprising Formula (I) or a pharmaceutically acceptable salt or a prodrug thereof, wherein a dashed line represents the presence or absence of a bond; Y is a carboxylic acid, sulfonic acid, or phosphonic ac...
|
WO/2006/047476A2 |
A compound comprising a prodrug of a prostaglandin EP4 agonist, wherein said prodrug is an ester, ether, or amide of a carbohydrate; or said prodrug is an ester, ether, or amide of an amino acid is disclosed herein. Maintenance of the co...
|
WO/2006/041875A1 |
Disclosed herein are compositions comprising an amide related to a prostaglandin and a biogenic amine. Other aspects relate to certain chemical compounds, pharmaceutical compositions, and methods of treating glaucoma.
|
WO/2005/068421A1 |
Prostaglandin nitrooxyderivatives having improved pharmacological activity and enhanced tolerability are described. They can be employed for the treatment of glaucoma and ocular hypertension.
|
WO/2005/061449A1 |
A compound selected from Formula (iv) or Formula (iii); (iv) (1R,2S)-2[4-1(S)-hydroxyhexyl)phenyl]-5-oxo-cyclopentanehept
anoic acid [RSS] or (iii) (1R,2S)-2[4-1(R)-hydroxyhexyl)phenyl]-5-oxo-cyclopentanehept
anoic acid [RSR] or a salt, ...
|